Blog

Nicholas DeVito: Gli2 promotes tumor immune evasion and immunotherapy resistance through Wnt and Prostaglandin signaling

Nicholas DeVito/scholars.duke.edu

Feb 26, 2025, 10:32

Nicholas DeVito: Gli2 promotes tumor immune evasion and immunotherapy resistance through Wnt and Prostaglandin signaling

Nicholas DeVito, Assistant Professor of Medicine at Duke University, Division of Medical Oncology, shared a paper he and his colleagues authored on LinkedIn:

“After 7 years of work our manuscript is published in Cancer Research

Here we describe how the hedgehog pathway transcription factor Gli2 promotes tumor immune evasion and immunotherapy resistance through Wnt and Prostaglandin signaling, which can be overcome with clinical pharmacologic inhibitors.

See the tutorial on BlueSky here.”

Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling

Authors: Nicholas C DeVito et al.

Nicholas DeVito

Balamayooran Theivanthiran Brent A. Hanks cancer Georgia M. Beasley Kaylee A. Villarreal Michael Aksu Michael P. Plebanek Michael Sturdivant Nagendra Yarla Nicholas C. DeVito OncoDaily Oncology Vaibhav Jain Y-Van Nguyen

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial

New World Cancer Declaration 2025–2035 by UICC

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that